KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Receivables: 2009-2024

Historic Change in Receivables for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Dec 2024 value amounting to $86.5 million.

  • Alnylam Pharmaceuticals' Change in Receivables rose 978.03% to $399.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $603.7 million, marking a year-over-year increase of 2505.26%. This contributed to the annual value of $86.5 million for FY2024, which is 1.58% down from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Change in Receivables stood at $86.5 million for FY2024, which was down 1.58% from $87.9 million recorded in FY2023.
  • Alnylam Pharmaceuticals' Change in Receivables' 5-year high stood at $101.8 million during FY2021, with a 5-year trough of $45.6 million in FY2022.
  • Moreover, its 3-year median value for Change in Receivables was $86.5 million (2024), whereas its average is $73.4 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first spiked by 132.02% in 2020, then crashed by 55.21% in 2022.
  • Alnylam Pharmaceuticals' Change in Receivables (Yearly) stood at $56.2 million in 2020, then skyrocketed by 81.02% to $101.8 million in 2021, then plummeted by 55.21% to $45.6 million in 2022, then soared by 92.86% to $87.9 million in 2023, then declined by 1.58% to $86.5 million in 2024.